

# Andres Iñiguez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6108297/publications.pdf>

Version: 2024-02-01

17  
papers

888  
citations

933447

10  
h-index

940533

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1293  
citing authors

#	ARTICLE	IF	CITATIONS
1	Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 1482-1490.	13.7	412
2	Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. <i>Lancet, The</i> , 2016, 387, 357-366.	13.7	174
3	Comparison of Newer-Generation Drug-Eluting With Bare-Metal Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 55-63.	2.9	96
4	1-Year Results of the REMEDEE Registry. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1127-1134.	2.9	45
5	Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. <i>EuroIntervention</i> , 2011, 7, 977-984.	3.2	41
6	One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent. <i>International Journal of Cardiology</i> , 2017, 226, 60-64.	1.7	20
7	Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial. <i>EuroIntervention</i> , 2013, 9, 328-335.	3.2	20
8	Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. <i>International Journal of Cardiology</i> , 2019, 283, 67-72.	1.7	19
9	Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, E31-E37.	1.7	13
10	Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry. <i>Open Heart</i> , 2017, 4, e000634.	2.3	13
11	Three-year clinical outcomes after dual-therapy COMBO stent placement: Insights from the REMEDEE registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 342-347.	1.7	8
12	Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresorbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 175-184.	1.7	8
13	Resultados tras 6 años de funcionamiento de la red asistencial de reperfusión coronaria de pacientes con infarto agudo de miocardio en la Comunidad de Galicia-Área Sur (PROGALIAM Sur). <i>Revista Espanola De Cardiologia</i> , 2013, 66, 506-507.	1.2	7
14	Final five-year results of the REMEDEE Registry: Real-world experience with the dual-therapy COMBO stent. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 503-510.	1.7	6
15	Long-term impact of diabetes in patients with ST-segment elevation myocardial infarction: Insights from the EXAMINATION randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 917-925.	1.7	5
16	1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration. <i>International Journal of Cardiology</i> , 2020, 307, 17-23.	1.7	1
17	Results After 6 Years of the Health Care Network for Coronary Reperfusion in Patients With Acute Myocardial Infarction in the Southern Area of Galicia (PROGALIAM-South). <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 506-507.	0.6	0